Zobrazeno 1 - 5
of 5
pro vyhledávání: '"L Carrasco Piernavieja"'
Autor:
L Carrasco Piernavieja, I Salvador Llana, B Sanchez Pascual, E Zhan Zhou, M Leal Alvarez, AM Duro Martinez, P Sanmartin Fenollera, M Perez Encinas
Publikováno v:
Section 4: Clinical pharmacy services.
Autor:
L Carrasco Piernavieja, JJ Martínez Simón, S Sanz Márquez, M. D. C. Morales Catalan, M Pérez Encinas, I Plo Seco, S. Lorenzo Martínez, I. Oterino Moreira, E Zhan Zhou, P. Roldan Navarro, I. Salvador Llana
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance In response to the COVID-19 pandemic, scientific societies and regulatory agencies quickly reviewed any available evidence to fill the therapeutic gap In this context, many drugs were used with an uncertain benefit- risk pro
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance Immunotherapy stimulates the body’s natural defences to fight tumour cells. In the literature, it is considered a safe drug. However, one of the adverse reactions described in the data sheet as uncommon is autoimmune pancr
Autor:
M Pérez Encinas, AM Martín De Rosales Cabrera, E Zhan Zhou, MI Barcia Martin, L Borrega Canelo, L Carrasco Piernavieja, M Domínguez Bachiller
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Patient beliefs about medication tools can measure patient concerns and the necessity for different long term treatment options, and can be related to adherence and quality of life (QoL). Aim and objectives To determine beli
Autor:
L Carrasco Piernavieja, AM Martín De Rosales Cabrera, E Zhan Zhou, M Domínguez Bachiller, Marcos Salazar, M Pérez Encinas
Publikováno v:
Section 3: Production and Compounding.
Background and importance Otomycosis is a suppurative fungal infection that affects the external auditory canal. Patients have a high rate of recurrence and are prone to invasive fungal infections after receiving limited therapeutic options with low